---
title: "RPC released its performance for the first half of the year, with a net profit attributable to the parent company of 290 million yuan, a decrease of 13.87%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254388609.md"
description: "According to the Zhitong Finance APP, RPC released its semi-annual report for 2025, showing that the company's operating revenue was 1.975 billion yuan, a year-on-year decrease of 16.46%. The net profit attributable to shareholders of the listed company was 290 million yuan, a year-on-year decrease of 13.87%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 207 million yuan, a year-on-year decrease of 17.88%. The basic earnings per share were 0.2075 yuan"
datetime: "2025-08-25T08:01:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254388609.md)
  - [en](https://longbridge.com/en/news/254388609.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254388609.md)
---

# RPC released its performance for the first half of the year, with a net profit attributable to the parent company of 290 million yuan, a decrease of 13.87%

According to the Zhitong Finance APP, RPC (000650.SZ) released its semi-annual report for 2025, showing an operating income of 1.975 billion yuan, a year-on-year decrease of 16.46%. The net profit attributable to shareholders of the listed company was 290 million yuan, a year-on-year decrease of 13.87%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 207 million yuan, a year-on-year decrease of 17.88%. The basic earnings per share were 0.2075 yuan

### Related Stocks

- [000650.CN](https://longbridge.com/en/quote/000650.CN.md)

## Related News & Research

- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [Curql invests in pet healthcare platform Wagmo](https://longbridge.com/en/news/296396050.md)
- [09:02 ETEvolved By Nature's Peptide Platform Used in FDA-Cleared Prescription Therapy for the Management of Atopic Dermatitis](https://longbridge.com/en/news/296496101.md)
- [13:22 ET/C O R R E C T I O N -- Rayence/](https://longbridge.com/en/news/296256530.md)